Is Age an Independent Risk Factor for Chemically Induced Acute Myelogenous Leukemia in Children?
- 11 July 2007
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Toxicology and Environmental Health, Part B
- Vol. 10 (5), 379-400
- https://doi.org/10.1080/15287390600975061
Abstract
Secondary or therapy-related acute myelogenous leukemia (t-AML) is a rare but unfortunate consequence of treatment with certain classes of cytotoxic chemotherapeutic agents or chronic exposure to high concentrations of benzene. Drugs known to produce AML following chemotherapy of primary malignancy are usually alkylating agents or topoisomerase II inhibitors. Both children and adults develop AML following treatment with these classes of antineoplastic drugs. In this review, the effect of age at treatment on a child's susceptibility to developing therapy related AML was investigated. The clinical literature describing pediatric cancer patients treated with cytotoxic chemotherapeutic agents was used to characterize risk factors associated with chemical leukemogenesis in children. As demonstrated in the published literature, the risk of developing AML following chemotherapy is not reliably correlated with the age of the pediatric patient. There is no consistent evidence that indicates that younger children will be at increased risk; in fact, some studies suggest that younger children might actually display a decreased susceptibility. The age dependency of treatment-related malignancies (all types) in children appears to vary considerably with the type of secondary neoplasm in question. For example, secondary solid tumors such as breast, central nervous system (CNS), bone, and thyroid cancer are highly dependent on the age of the patient at time of diagnosis and treatment; in contrast, an age dependency for t-AML risk was not observed in these same patient populations. Predictably, the induction of t-AML in children follows a rational dose-response relationship, with increasing doses of chemotherapy resulting in greater risk. Recent U.S. Environmental Protection Agency (EPA) cancer risk assessment guidance recommends a default assumption that children are inherently up to 10-fold more sensitive than adults to carcinogen exposures. Available scientific and medical literature does not support the hypothesis that children necessarily possess an increased risk of developing AML following leukemogenic chemical exposure.Keywords
This publication has 66 references indexed in Scilit:
- Therapy-Related Acute Promyelocytic LeukemiaJournal of Clinical Oncology, 2003
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- Treatment of paediatric Hodgkin's disease: a balance of risksEuropean Journal Of Cancer, 2002
- Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries.BMJ, 1993
- Leukemia Following Hodgkin's DiseaseThe New England Journal of Medicine, 1990
- Treatment-Related LeukemiaThe New England Journal of Medicine, 1990
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 1989
- Benzene and LeukemiaThe New England Journal of Medicine, 1987
- A Quantitative Estimate of Leukemia Mortality Associated with Occupational Exposure to Benzene3Risk Analysis, 1982
- Dose-Response Relationship of Neutrons and γ Rays to Leukemia Incidence among Atomic Bomb Survivors in Hiroshima and Nagasaki by Type of Leukemia, 1950-1971Radiation Research, 1979